Table 1 The characteristics of included studies
From: Outcomes of platelet-rich plasma for plantar fasciopathy: a best-evidence synthesis
Study(Year) | Sex,na,(M/F)b | Age,Mean(SD) | Groups,n | Treatment Schedules | Assessment Methods | Follow-up, Month | ||
|---|---|---|---|---|---|---|---|---|
PRP | CS/PL | PRP | CS/PL | |||||
Omar AS (2012) [32] | 30(0/30) | PRP:42.5(17.5) CS:44.5(15.5) | 15 | 15 | 1 dose of P-PRP was injected | 1 dose of CS injected | VAS; FHSQ | 1 |
Lee TG (2007) [33] | 64/(4/57) | PRP:48.3(10.5) CS:49.2(11.1) | 30 | 31 | 1 dose(1.5 ml) of autologous blood mixed with 1 ml of Lignocaine HCL 2% was injected | a combination of 20 mg (0.5 ml of a 40 mg/ml solution) of Triamcinolone Acetonide with 2 ml of Lignocaine HCL 1% was used | VAS; TT | 1;3;6 |
Aksahin E (2012) [34] | 60(25/35) | PRP:46.36(8.49) CS:45.47(9.36) | 30 | 30 | 1 dose(3mL) P-PRP was injected after 2 mL of 2% prilocaine injection | 1 does of 2 mL of 40 mg Methylprednisolone with 2 mL of 2% prilocaine was injected | VAS; MRMS | 6 |
Carlos AO (2017) [35] | 32(6/24) | PRP:44.8(0) CS:44.8(0) | 15 | 15 | 1 dose of P-PRP(3 mL) activated with 0.45 mL of 10% calcium gluconate was injected | 1 dose (8 mg) of dexamethasone plus 2 mL of lidocaine was injected | VAS; FADI; AOFAS | 1;2;3;4 |
Tiwari M (2013) [36] | 60(3/57) | NC | 30 | 30 | 1 dose(5ml) of P-PRP was injected | 1 dose of CS was injected | VAS | 1;3;6 |
Monto RR (2014) [13] | 40(17/23) | PRP:59(0) CS:51(0) | 20 | 20 | a single ultra-sound guided injection of autologous P-PRP was injected | a single ultrasound guided injection of 40 mg DepoMedrol cortisone | AOFAS | 3;6;12;24 |
Jain K (2015) [37] | 46(6/40) | PRP:55.6(0) CS:55.6(0) | 23 | 23 | 1 dose(2.5ml) of P-PRP was injected | 1 dose of Triamcinolone (Kenalog) 40 mg and Levobupivacaine hydrochloride (Chirocaine) injection | VAS; AOFAS; MRMS | 3;6;12 |
Say F (2014) [38] | 50(11/39) | PRP:47(0) CS:48.6(0) | 25 | 25 | 1 dose(2.5ml) of P-PRP was injected | 1 dose of a mixture of 40 mg/1 ml of methylprednisolone and 1 ml of prilocaine was injected | VAS; AOFAS | 6 |
Sherpy NA (2016) [39] | 50(13/37) | PRP:37.48(8.75) CS:38.52(6.2) | 25 | 25 | 1 dose(3ml) of P-PRP was injected | 1 dose of triamcinolone acetonide (2ml ,40 mg/ml) was injected | VAS; FHSQ | 1.5;3 |
Vahdatpour B (2016) [40] | 32(9/23) | PRP:45.44(7.74) CS:47.12(10.70) | 16 | 16 | 1 dose(3ml) of P-PRP was injected | 1 dose of Methylprednisolone( 1 ml) plus lidocaine( 1 ml) was injected | VAS; MRMS | 1;3;6 |
Jain SK (2018) [41] | 80(46/34) | PRP:37.7(10.3) CS:38.9(9.5) | 40 | 40 | 1 dose(3ml) of P-PRP was injected | 1 dose of methyl prednisolone (2m,40 mg) with 2% lidocaine hydrochloride(2 mL) was injected | VAS; MRMS; AAOS; FAI; AOFAS | 1;3;6 |
Sarah JL (2019) [42] | 28(9/19) | PRP:47.9(10.702) Placebo:52.1(10.277) | 14 | 14 | 1 dose(3ml) of P-PRP was injected | 1 dose of saline injected | VAS | 6 |
Mahindra P (2016) [43] | 75(31/44) | PRP:30.72(7.42) CS:33.92(8.61) Pl:35.48(9.54) | 25 | 25 | 1 dose(3ml) of P-PRP was injected | CS:1 dose of CS injected PL:1 dose of saline injected | VAS; AOFAS | 3 |